- Home
- ACIW vs KNSA Comparison
ACIW vs KNSA Comparison
Compare ACIW & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACIW | KNSA |
|---|---|---|
| Founded | 1975 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 4.9B |
| IPO Year | 1996 | 2018 |
Fundamental Metrics
Financial Performance| Metric | ACIW | KNSA |
|---|---|---|
| Price | $51.08 | $79.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $67.33 | ★ $98.00 |
| AVG Volume (30 Days) | ★ 614.0K | 427.9K |
| Earning Date | 11-05-2026 | 10-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 13.09 | ★ 225.00 |
| EPS | ★ 0.69 | 0.27 |
| Revenue | ★ $1,009,780,000.00 | $677,564,000.00 |
| Revenue This Year | $8.27 | $46.66 |
| Revenue Next Year | $7.61 | $22.90 |
| P/E Ratio | ★ $73.26 | $295.59 |
| Revenue Growth | N/A | ★ 60.09 |
| 52 Week Low | $38.05 | $35.53 |
| 52 Week High | $61.08 | $82.94 |
Technical Indicators
Market Signals| Indicator | ACIW | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 52.30 | 59.13 |
| Support Level | $50.96 | $73.81 |
| Resistance Level | $51.65 | $81.42 |
| Average True Range (ATR) | 1.01 | 2.60 |
| MACD | 0.29 | 0.36 |
| Stochastic Oscillator | 87.24 | 78.79 |
Price Performance
Historical ComparisonAbout ACIW ACI Worldwide Inc.
ACI Worldwide Inc develops, markets, and installs a portfolio of software products focused on facilitating electronic payments. The firm's products are sold and supported directly and through distribution networks covering three geographic regions - the Americas, EMEA, and Asia Pacific. ACI software products process payment transactions for retail banking clients, billers such as utilities and healthcare providers, and community banks and credit unions. ACI's customers are financial institutions all over the world, but the majority of the revenue is generated in the United States and EMEA regions. The company's operating segment includes Payment Software and Biller. The company generates the majority of its revenue from the Payment Software segment.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.